WO1993010793A1 - Agent antiviral - Google Patents

Agent antiviral Download PDF

Info

Publication number
WO1993010793A1
WO1993010793A1 PCT/RU1992/000170 RU9200170W WO9310793A1 WO 1993010793 A1 WO1993010793 A1 WO 1993010793A1 RU 9200170 W RU9200170 W RU 9200170W WO 9310793 A1 WO9310793 A1 WO 9310793A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
sρedsτvο
dηκ
pροτivοviρusnοe
chτο
Prior art date
Application number
PCT/RU1992/000170
Other languages
English (en)
Russian (ru)
Inventor
Jury Petrovich Vainberg
Elli Nikolaevna Kaplina
Original Assignee
Jury Petrovich Vainberg
Elli Nikolaevna Kaplina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jury Petrovich Vainberg, Elli Nikolaevna Kaplina filed Critical Jury Petrovich Vainberg
Publication of WO1993010793A1 publication Critical patent/WO1993010793A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention is in the medical field, and more precisely, in a new medical device. 5 PREVIOUS LEVEL OF TECHNOLOGY
  • chemo-therapeutic agents are widely known, causing death of the virus or inhibiting their development, which are used for the treatment and treatment of virus infections.
  • the effect of these devices is directed to different stages of the US production of viral particles in human cells. or lively.
  • Separate industrial products are different as far as the mechanism of action is concerned, as is the use of active substances in the case of 15
  • kerocide an addictive substance
  • this product is highly effective and is used only for 0 for local use in patients with ocular disease; It also has a number of adverse effects (discharge of the conjunctiva, leakage of eyelids).
  • the computer has been known to interfere with the synthesis and replication of virus particles.
  • adamantamines are derivatives of adamantamines (amantadine, remantadine), which inhibit the earlier stages of the reproduction of the virus of the group. These drugs are most active in relation to the type of virus and find less than 0 For the treatment and treatment of the disease only.
  • Zayavlyaem ⁇ e s ⁇ eds ⁇ v ⁇ m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ in ⁇ azlich- ny ⁇ ⁇ a ⁇ matsev ⁇ iches ⁇ i ⁇ ig ⁇ dny ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ ⁇ ma ⁇ (in vi- de ine ⁇ tsy, ⁇ as ⁇ v ⁇ v, su ⁇ zi ⁇ iev and d ⁇ ugi).
  • a device in the form of injections it is only constituent that contains active material in quantities
  • the claimed medication may contain any kind of suitable diluent.
  • the claimed product is preferably in the form of injections or disposable preparations for use in a diluent-supplied water.
  • Zayavlyaem ⁇ e ⁇ iv ⁇ vi ⁇ usn ⁇ e s ⁇ eds ⁇ v ⁇ ⁇ bladae ⁇ vys ⁇ - ⁇ y ⁇ iv ⁇ vi ⁇ usn ⁇ y a ⁇ ivn ⁇ s ⁇ yu ⁇ ⁇ n ⁇ sheniyu ⁇ -D ⁇ s ⁇ de ⁇ z haschim vi ⁇ usam (vi ⁇ usu ge ⁇ esa) and ⁇ ⁇ -s ⁇ de ⁇ zhaschim vi ⁇ usam ( ⁇ mi ⁇ s ⁇ vi ⁇ usam - v ⁇ zbudi ⁇ elyam g ⁇ i ⁇ a, ⁇ a ⁇ ami ⁇ s ⁇ vi ⁇ usu - v ⁇ zbudi ⁇ elyu ⁇ l ⁇ yadny ⁇ plague, ⁇ e ⁇ vi ⁇ usu - v ⁇ zbudi ⁇ elyu AIDS).
  • natrium salt of the naive had a molecular weight of 300-500 kDa.
  • THIS EXCEEDS PROSPECTS - 4 the nomenclature of the complex in the body of a human organism or living and contributes to the improvement of its digestibility.
  • Compounds of sodium nativity with the indicated fuel metals taken in the ratio of 10-1000: 0.5-3.0, have the advantage of an effective activity. Relationships of the above and the below-mentioned divisions of the divisions adversely affect the activity of the claimed assets.
  • the claimed system is dominated by active activity in the case of the virus of the virus, the virus - the virus, the virus.
  • the cages were incubated for 3-4 days in an atmosphere of 5 ⁇ ⁇ and 98 $ of humidity at a temperature of 37 ° ⁇ . For each type of virus, at least 2 parallel operations were introduced.
  • the pressure was divided: a) a complete pressure of the virus group was observed due to the concentration of the claimed 400-500 mkg / ml; b) The total pressure of the Herpes spp. virus is observed at a concentration of 500-600 mcg / ml; c) A complete suppression of the plague virus is completely observed, with a concentration of 800-900 mcg / ml.
  • z / He, ⁇ 10: 3; 350: 0.5 1000: 1, with an active substance concentration of 5 mg / ml.
  • the tests were carried out in comparison with the known - - with a preparation with azidothymidine (aqueous solution with a concentration of 5 mg / ml of the active substance).
  • the cells were cultured at a concentration of 0.3-0.5x10 e cells in I ml of salmon nn ⁇ 1640 with 10 $ fetal calves, 300 g / ml of glutamine, and 100 g / ml of gene were diluted. The life of the cage was shared by a 0.4-share of the market. As a source of the virus, they used the ⁇ ICH- ⁇ / ⁇ 8 strain, highlighted in the Institute of Virology named after D.I.Ivanovsk, and group of highly infectious viruses. The division of the antigenic activity of the preparations was carried out in 96-well plastic panels (the “Dinatec” company, Switzerland) according to the known immunoassay. The study of human immunodeficiency virus products was carried out by taking into account virus-induced syncytia in cell cultures.
  • the suspension of the cassettes were placed in plastic 24-well panels, they treated the patient for various conditions.
  • the infectiousness of infection amounted to 0.01 ⁇ TsZ 50 / clet.
  • the cells were incubated at 37 ° C in atmosphere 5, with ⁇ 0 2 and 98 $ humidity for 5-7 days after taking into account the results.
  • the claimed assets are also available on the basis of D ⁇ -Ms with ⁇ or on the basis of D ⁇ - ⁇ a with ⁇ , ⁇ , ⁇ , ⁇ £.
  • the glue protection - - The effect of the virus was lower.
  • the claimed preparation on the basis of ⁇ - ⁇ , with ⁇ , an effective effect was observed only in a concentration of 1600 g / ml. With this, the number of viral induced syncnts decreased only 2 times.
  • the claimed medium on the basis of D-Ms was previously effective in the concentration of 400-1600 g / mp.
  • doses of 800–1600 g / ml their potent effect was compatible with the beneficial activity of azidothymidine.
  • the study of cases of neglect indicates the absence of a toxic effect in the case of the use of all variants of the treatment (1,600 cases).
  • the claimed medium is a minor one.
  • mice were administered intramuscularly, a maximum dose of 1,500 mg / kg was not observed, there were no significant toxic effects.
  • the claimed medium has been tested in clinics in Lviv, a large SDS.
  • the drug was prescribed for oral administration in doses of 300 to 1200 mg for administration of 1-2 times per day for 30 days. Observations indicated that there was no other harmful effect in all cases.
  • the product was reactivated by activating the activity of the immune system, increasing the content of all types of lymphomas in the body. Patients felt better, ' they had normalized temperature, showed symptoms, they began to lose weight.
  • Table 5 below shows the effect of the claimed drug on the state of the immunological system. "
  • the inventive medium can be used in any other medicinal formulations, is predominantly used as an industrial solution
  • the medicinal formulations of the claimed medication are prepared by well-known methods.
  • the material in question is the property of the natur- al salt, which is safe for people to eat and has the advantage of being completely non-hazardous.
  • the claimed medium is used in the form of injectable substances with a content of active substance of 1.5 wt. $ Or of a consumable for direct use of which consumes $ 3.
  • the claimed device does not have any other beneficial effects or indications for use.
  • the claimed inventive medication is used in medicine and veterinary medicine for the treatment of diseases caused by various types of viral infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un agent antiviral contient une substance active, un complexe d'un sel de sodium d'ADN natif avec un métal polyvalent choisi parmi Ni, Fe, Co, Mn, Mg ou Zn pris à un rapport molaire de 10-1000:0,5-3,0, respectivement, et un diluant pharmaceutique. L'agent de l'invention a une activité virale contre le virus herpétique, l'orthomyxo-virus - virus de la grippe, le paramyxo-virus - virus de la peste des carnivores, et contre des rétrovirus, y compris le virus de l'immunodéficience humaine.
PCT/RU1992/000170 1991-12-03 1992-09-09 Agent antiviral WO1993010793A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SU5015754 1991-12-03
SU5015754/14 1991-12-03

Publications (1)

Publication Number Publication Date
WO1993010793A1 true WO1993010793A1 (fr) 1993-06-10

Family

ID=21591133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1992/000170 WO1993010793A1 (fr) 1991-12-03 1992-09-09 Agent antiviral

Country Status (1)

Country Link
WO (1) WO1993010793A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818202A1 (fr) * 1994-09-29 1998-01-14 Nauchno-Proizvodstvennoe Predpriyatie "Farmek" Hybride d'adn-arn et preparation d'adn, procedes d'obtention dudit hybride et de ladite preparation a partir de laitance d'esturgeon, et compose pharmaceutique a base dudit hybride d'adn-arn
WO2002043740A1 (fr) * 2000-12-01 2002-06-06 Veritas S.R.L. Procede de fabrication d'un produit antiviral immunotropique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135312A2 (fr) * 1983-07-27 1985-03-27 Pharmaceuticals Limited Scotia Compositions antivirales
FR2598619A1 (fr) * 1986-05-16 1987-11-20 Mafitra Management Services In Medicament antiviral a base d'acide nucleique modifie, et son procede de preparation
DE3724951A1 (de) * 1987-07-28 1989-02-09 Werner E G Prof Dr Mueller Arzneimittel, enthaltend modifizierte desoxyribonukleinsaeure und dessen verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135312A2 (fr) * 1983-07-27 1985-03-27 Pharmaceuticals Limited Scotia Compositions antivirales
FR2598619A1 (fr) * 1986-05-16 1987-11-20 Mafitra Management Services In Medicament antiviral a base d'acide nucleique modifie, et son procede de preparation
DE3724951A1 (de) * 1987-07-28 1989-02-09 Werner E G Prof Dr Mueller Arzneimittel, enthaltend modifizierte desoxyribonukleinsaeure und dessen verwendung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818202A1 (fr) * 1994-09-29 1998-01-14 Nauchno-Proizvodstvennoe Predpriyatie "Farmek" Hybride d'adn-arn et preparation d'adn, procedes d'obtention dudit hybride et de ladite preparation a partir de laitance d'esturgeon, et compose pharmaceutique a base dudit hybride d'adn-arn
EP0818202A4 (fr) * 1994-09-29 2000-05-10 Npp Farmek Hybride d'adn-arn et preparation d'adn, procedes d'obtention dudit hybride et de ladite preparation a partir de laitance d'esturgeon, et compose pharmaceutique a base dudit hybride d'adn-arn
WO2002043740A1 (fr) * 2000-12-01 2002-06-06 Veritas S.R.L. Procede de fabrication d'un produit antiviral immunotropique
EP1338281A4 (fr) * 2000-12-01 2004-03-24 Veritas S R L Procede de fabrication d'un produit antiviral immunotropique

Similar Documents

Publication Publication Date Title
US5523232A (en) Use of restriction endonucleases against viruses, including HIV
EP0601164B1 (fr) Procedes pour le traitement d'infections virales
WO1992021368A1 (fr) Composition et procede de traitement de maladies
WO1996022777A1 (fr) Melanges de di-desoxynucleosides et d'hydroxycarbamide pour inhiber la propagation de retrovirus
EP0630644A4 (fr) Compose pharmaceutique anti-microbien et induisant des interferons.
AU2006212322A1 (en) Use of iron(III) complex compounds
CN104127402A (zh) 双环铂在制备抗病毒药物和抗菌药物中的应用
CA2386325C (fr) Complexes de gallium de 3-hydroxy-4-pyrones destines au traitement d'infections par des procaryotes intracellulaires, des virus a adn et des retrovirus
AU709620B2 (en) New applications of lysozyme dimer
WO2003072124A1 (fr) Methode d'induction de differentiation cellulaire
MXPA06013050A (es) Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias.
WO1993010793A1 (fr) Agent antiviral
EA003100B1 (ru) Лечебный препарат вирулицидного действия
JPH06199697A (ja) 抗ウイルス・抗菌・殺菌剤
RU2697887C1 (ru) Средство, обладающее противовирусным действием в отношении вирусов клещевого энцефалита и герпеса простого I типа
MELLERT et al. Inhibition of HIV-1 replication by an antiviral xanthate compound in vitro
EP0236487A1 (fr) Inactivation d'un virus
Fitzwilliam et al. Experimental encephalitis caused by herpes simplex virus: comparison of treatment with tilorone hydrochloride and phosphonoacetic acid
EP0255420A2 (fr) Agent antiviral d'inhibition de la croissance du virus du syndrome immuno-deficitaire acquis (SIDA)
JPH01149730A (ja) レトロウイルス増殖抑制剤
RU2440128C1 (ru) Способ комплексной патогенетической терапии острых форм вирусного гепатита в и микст-гепатитов (в+с, в+d, в+с+d)
RU2264819C2 (ru) Фармацевтическая противогерпетическая композиция и способ получения лекарственной формы на ее основе
RU2182828C1 (ru) Композиция, обладающая антивич и антигерпесной активностью
RU2005475C1 (ru) Противовирусное средство
Soike et al. Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-β

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA